Cell and Gene Logistics

  1. Ultra-Low Temperature Freezer With Enhanced Security Features 7/3/2025

    PHCbi brand's 18.6 cu.ft (528L) ultra-low temperature freezer offers the flexibility of operating on both 115V or 220V with the switch of a power cord. This model provides enhanced security features and operates at only 4.99kWh per day. SMART features include three lock methods: facial recognition, keypad, or optional proximity card. ENERGY STAR® Certified.

  2. Mitigate Frost Buildup With This Ultra-Low Temperature Freezer 7/3/2025

    PHCbi brand’s 25.6 cu.ft (725L) FrostLess ultra-low temperature freezer provides reliable temperatures as low as -86°C. It is engineered to mitigate frost buildup more than our category-leading models while maintaining the reliability and energy efficiency that today's laboratories require. It operates on 115V and uses only 7.9kWh per day. ENERGY STAR® Certified.

  3. Unlocking The Cold Chain Of Proteins 7/3/2025

    Discover how controlled freezing minimizes cryoconcentration and protein denaturation in bulk drug substances. Learn about efficient, scalable freezing solutions for enhanced product stability.

  4. Integrated Services: Expertise At Every Step 7/2/2025

    Bringing cell and gene therapies to market is complex, but with the right partner, you can overcome challenges and simplify, support, and scale your therapy from development to commercialization.

  5. Lab Oversupply Is Pushing Leasing, Rent and Relocation Down 7/1/2025

    The landscape of the U.S. pharmaceutical lab market is changing, according to JLL’s U.S. Life Sciences Property Report. In addition to the effort to bring pharma manufacturing back to the U.S. ahead of looming tariffs, an oversupply of space and lower tenant demand in large biopharma markets is dropping leasing rates, rent costs and lease duration, among other changes.

  6. CAR-T Innovation: Balancing Allogeneic And Autologous Cell Therapy 6/30/2025

    Join experts as they discuss strategies for optimizing allogeneic and autologous therapies, aiming for balanced development and wider patient accessibility by 2030.

  7. Why 'Which Is Best?' Is The Wrong Question In CGT Development 6/27/2025

    In cell therapy development, the instinct to seek a single “best” option is natural — but in reality, there’s rarely a universal winner.

  8. Starting Smart: Building Early CGT Supply Chains 6/26/2025

    Discover how building a scalable, compliant supply chain can set your CGT program up for long-term success and avoid risks that could derail progress down the line.

  9. Securing INmune Bio's Trial Materials In A Crisis 6/26/2025

    Discover how a sudden biostorage shutdown put INmune Bio’s trial at risk, revealing the critical importance of logistics and rapid coordination in protecting advanced therapy programs.

  10. Single-Use Solutions: Cryopreservation 6/26/2025

    As advanced therapy manufacturing evolves, maintaining the integrity of biological materials during cryopreservation steps is ever more critical.